Patients with unresectable cancer causing distal bile duct obstruction requiring, suitable for and would undergo endoscopic biliary drainage. EUS-guided hepaticogastrostomy (EUS-HGS), endoscopic retrograde cholangiopancreatography (ERCP), malignant distal biliary obstruction (MDBO)
Conditions
Interventions
biliary obstruction (RBO) rate between the ERCP and the EUS-HGS in patients with cancer having distal bile duct obstruction,biliary obstruction (RBO) rate between the ERCP and the EUS-HGS in patients
Supportive Care,Supportive Care
1biliary obstruction (RBO) rate between the ERCP and the EUS-HGS in patients with cancer having distal bile duct obstruction,2 biliary obstruction (RBO) rate between the ERCP and the EUS-HGS in patien
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with unresectable cancer causing distal bile duct obstruction requiring, suitable for and would undergo endoscopic biliary drainage. Patients in a reasonably good physical condition (ECOG2). Patients with life expectancy longer than 6 months. Patients with viable liver volume more than 80%. Patients without preceding hepatectomy or atrophic liver. Patients without cirrhosis child B or C. Patients without significant ascites that might preclude EUS-HGS.
Exclusion criteria
Exclusion criteria: Exclusion criteria Patients with hilar bile duct obstruction. Patients with abnormal blood clotting or platelet function that cannot be corrected (INR < 1.5 or platelet count <50,000). Pregnant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the 6-month RBO rate between the self-expanding metal stent placed to treat bile duct obstruction due to cancer using ERCP technique and the EUS-HGS technique at 6 months after end of the intervention EUS-guided hepaticogastrostomy (EUS-HGS), endoscopic retrograde cholangiopancreatography (ERCP) | — |
Secondary
| Measure | Time frame |
|---|---|
| The differences in the technical success rate, clinical success rate, survival rate, patency time, quality of life, and incidence of adverse events at 6 months after end of the intervention EUS-guided hepaticogastrostomy (EUS-HGS), endoscopic retrograde cholangiopancreatography (ERCP) | — |
Countries
Thailand
Contacts
Public Contactpradermchai kongkam
Chulalongkorn University
Outcome results
None listed